EVOX THERAPEUTICS

WIPO WIPO 2016

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark EVOX THERAPEUTICS was filed as Word mark on 12/15/2016 at the World Intellectual Property Organization.

Trademark Details Last update: April 7, 2023

Trademark form Word mark
File reference 1348112
Register number UK00003168512
Countries Australia China Japan United States of America (USA)
Base trademark GB No. UK00003168512, September 16, 2016
Application date December 15, 2016
Expiration date December 15, 2026

Trademark owner

King Charles House,
Park End Street
GB

Trademark representatives

80 Turnmill Street London EC1M 5QU GB

goods and services

05 Pharmaceuticals; pharmaceutical preparations and substances; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; medicine; medical preparations and articles; biological preparations for medical purposes; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosome; biological preparations comprising a therapeutic target protein-loaded exosome; biological preparations comprising exosome for pharmaceutical purposes; biological reagents for medical use; mixed biological preparations for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutics for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy
42 Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services; biological research; clinical research; providing medical and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science
44 Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; laboratory analysis service relating to the diagnosis and treatment of persons; medical analysis and examinations; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy

Trademark history

Date Document number Area Entry
April 5, 2023 2023/14 Gaz US Rejection
December 1, 2022 2022/50 Gaz Correction
December 16, 2020 2020/52 Gaz CN Rejection
August 3, 2020 2020/32 Gaz Correction
May 18, 2020 2020/21 Gaz Deletion
March 15, 2018 2018/16 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
October 26, 2017 2017/43 Gaz JP Rejection
October 18, 2017 2017/44 Gaz EM Rejection
September 21, 2017 2017/38 Gaz AU Rejection
June 20, 2017 2017/25 Gaz US Rejection
December 15, 2016 2017/20 Gaz GB Registration

ID: 141348112